Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma.
Bozec A, Ilie M, Dassonville O, Long E, Poissonnet G, Santini J, Chamorey E, Ettaiche M, Chauvière D, Peyrade F, Hebert C, Benezery K, Sudaka A, Haudebourg J, Selva E, Hofman P. Bozec A, et al. Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2745-9. doi: 10.1007/s00405-013-2399-y. Epub 2013 Feb 22. Eur Arch Otorhinolaryngol. 2013. PMID: 23430081
In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.
Ilie MI, Lassalle S, Long-Mira E, Hofman V, Zangari J, Bénaim G, Bozec A, Guevara N, Haudebourg J, Birtwisle-Peyrottes I, Santini J, Brest P, Hofman P. Ilie MI, et al. Among authors: bozec a. Virchows Arch. 2013 Sep;463(3):437-44. doi: 10.1007/s00428-013-1453-x. Epub 2013 Jul 27. Virchows Arch. 2013. PMID: 23893334
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P. Ilie MI, et al. Among authors: bozec a. Thyroid. 2014 May;24(5):858-66. doi: 10.1089/thy.2013.0302. Epub 2014 Mar 6. Thyroid. 2014. PMID: 24417277
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, Catargi B, Peyrottes I, Sadoul JL, Bordone O, Bonnetaud C, Butori C, Bozec A, Guevara N, Santini J, Hénaoui IS, Lemaire G, Blanck O, Vielh P, Barbry P, Mari B, Brest P, Hofman P. Lassalle S, et al. Among authors: bozec a. Oncotarget. 2016 May 24;7(21):30461-78. doi: 10.18632/oncotarget.8458. Oncotarget. 2016. PMID: 27036030 Free PMC article.
Matrix Stiffening and EGFR Cooperate to Promote the Collective Invasion of Cancer Cells.
Grasset EM, Bertero T, Bozec A, Friard J, Bourget I, Pisano S, Lecacheur M, Maiel M, Bailleux C, Emelyanov A, Ilie M, Hofman P, Meneguzzi G, Duranton C, Bulavin DV, Gaggioli C. Grasset EM, et al. Among authors: bozec a. Cancer Res. 2018 Sep 15;78(18):5229-5242. doi: 10.1158/0008-5472.CAN-18-0601. Epub 2018 Jul 19. Cancer Res. 2018. PMID: 30026329
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: bozec a. Theranostics. 2021 Sep 21;11(19):9571-9586. doi: 10.7150/thno.61711. eCollection 2021. Theranostics. 2021. PMID: 34646387 Free PMC article.
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M. Hagege A, et al. Among authors: bozec a. Cell Rep Med. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659. Cell Rep Med. 2022. PMID: 36130479 Free PMC article.
259 results